ID: MRFR/LS/5167-HCR | 85 Pages | Published By Kinjoll Dey on March 2023
Aptamers Market will grow at CAGR of 18.10% to hit USD 1,724.5 million by 2030
$ 1,724.5 million
Aptamers Market Overview:
During the forecast period (2022–2030), the Aptamers Market is expected to grow at a significant CAGR of 18.10 percent. Aptamers are peptide compounds with high selectivity for binding to the targeted lipid, protein, or nucleic acid components. These are produced quickly and used in protein inhibition, specific detection, and characterization. With antibodies, small compounds, and other aptamers, aptamers can be employed as detection reagents, pharmacological leads, and functional proteomic levels.
Aptamers can be changed to have increased affinity and specificity to a large range of targets. Improvements in aptamer development methods, rising R&D spending, and a growing number of firms participating in this industry are some of the significant drivers driving market expansion. They're chemically manufactured, so there's no batch-to-batch variance and development takes less time. Continuous technological advancements are also projected to support growth.
The Global Aptamers Market has been segmented on the basis of type, application, technology and end users.
On the basis of type, the market has been classified as nucleic acid aptamers and peptide aptamers. The nucleic acid aptamers have been segmented into DNA-Based Aptamers, RNA-Based Aptamers.
On the basis of application, the market has been classified as diagnostics, therapeutics development, research and development, other applications
On the basis of technology, the market has been classified as Selex, X-aptamer and MARAS technique.
On the basis of end users, the market has been classified as academic and government research institutes, biotechnology and pharmaceutical companies, contract research organizations and other end users
On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.
The European aptamers market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The aptamers market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East and Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Global Aptamers Market Share, by Region, 2017 (%)
Source: MRFR Analysis
In the aptamers market, North America is anticipated to account for the largest market share due to the early adoption of advanced medical technologies and high investment and funding to support the development of aptamers. The other factor such as the growing demand for aptamer therapeutics coupled with a rise in a number of research laboratories helps to boost the market.
The European market is expected to hold the second largest market share. Factors such as a rise in research expenses, advancement of technology, the decline in human health, and the necessity for innovative and effective therapies boost the growth of the market in this region. The increasing number of small-scale start-ups, government organizations, rising number of products under clinical investigation, and growing number of academic research laboratories investigating the potential of aptamers are anticipated to support future growth of this market.
Whereas the market share in the Asia-Pacific region is also anticipated to experience growth in the near future due to access to optimal treatment facilities and growing demand for increasing government initiatives, advanced technology, better adoption rate, and rising healthcare expenditure.
The market in the Middle East & Africa is expected to account for the smallest share of the global aptamers market due to an underdeveloped healthcare sector, the dearth of technical knowledge, and poor medical facilities.Recent Development
Aptus Biotech is a biotech startup with the objective of becoming a leader in the creation of novel biotechnological applications using aptamers. The Ramon y Cajal Foundation, which has vast expertise in research and biomedical applications, supports Aptus management and technical staff. APTUS Biotech provides aptamer selection services such as oligonucleotide selection using the SELEX method, aptamer storage by bacterial insertion, chemical production of aptamers, and target protein binding investigations.
Following the failure of two phases III clinical trials (OPH1002 and OPH1003) of Ophthotech's proprietary anti-platelet-derived growth factor (anti-PDGF) drug, Fovista, in combination with Regeneron's Eylea (aflibercept) or Genentech's Avastin (bevacizumab) for the treatment of wet age-related macular degeneration, the company announced this week that the last Phase III clinical trial (OPH100 Fovista, on the other hand, is not the only medicine in Ophthotech's AMD pipeline. Zimura (avacincaptad pegol), a complement 5 (C5) inhibitor, is being developed by the business for the treatment of wAMD and geographic atrophy (GA), a type of dry AMD (dAMD).
Global Aptamers Market, by Type
Global Aptamers Market, by Application
Global Aptamers Market, by Technology
Global Aptamers Market, by End Users
Global Aptamers Market, by Region
|Market Size||Significant Value|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Type, Application, Technology And End Users|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Aptamer Sciences, Inc., Aptagen, LLC, Base Pair Biotechnologies, Inc., Ophthotech Corporation, Am Biotechnologies, LLC, Aptamer Solutions Ltd., Aptus Biotech S.L., Neoventures Biotechnology Inc., Somalogic, Inc., Trilink Biotechnologies, Inc., Vivonics, Inc., Noxxon Pharma|
|Key Market Opportunities||
|Key Market Drivers||Increasing R&D expenditure and constant technological advances|
The aptamers market is projected to grow at a 18.10% CAGR between 2020-2030.
North America is projected to command the largest share in the aptamers market.
It is widely used in research and development, therapeutics development, and diagnostics.
Increasing R&D expenditure and constant technological advances are adding market growth.
Inadequate regulatory structure may limit market growth.